Abstract
We read with interest the paper by Kalliokoski et al. (2020) investigating whether PBMCs collected from patients with dermatitis herpetiformis (DH) undergoing a 3-day oral gluten challenge react to gluten-derived gliadin in the enzyme-linked immunospot (ELISpot) assay similarly to those from patients with celiac disease (CD). Interestingly, the authors found that on stimulation with tissue transglutaminase (TG)-gliadin or either of the gliadin peptides, 7 of the 15 patients (47%) with DH and 15 of the 18 patients (83%) with CD were considered responders in the IFN-γ ELISpot assay.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
